Postoperative Pain
📧 Sign up to get email alerts when something new happens for Postoperative Pain.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-12-22FDA Approved: OXYCODONE AND ACETAMINOPHEN — Supplemental Application (KVK-Tech, Inc.)
FDA approved a supplemental application for a generic oxycodone and acetaminophen product from KVK-Tech, Inc.
-
FDA approval · 2025-12-22FDA Approved: OLINVYK — Supplemental Application (Trevena, Inc.)
The FDA approved a supplemental application for OLINVYK (oliceridine) from Trevena, Inc. This action updates the product labeling as part of…
-
FDA approval · 2025-12-22FDA Approved: DSUVIA — Supplemental Application (AcelRx Pharmaceuticals, Inc.)
FDA approved a supplemental application for DSUVIA (sufentanil) by AcelRx Pharmaceuticals, Inc., authorizing changes to the NDA. The approva…
-
FDA approval · 2025-12-22FDA Approved: MORPHINE SULFATE — Supplemental Application (Fresenius Kabi, USA LLC)
FDA approved a supplemental application for Morphine Sulfate submitted by Fresenius Kabi, USA LLC.
-
EMA approval · 2025-08-13EMA Authorised: Exparel liposomal (bupivacaine) — Pacira Ireland Limited
The European Medicines Agency has authorised Exparel liposomal (bupivacaine) by Pacira Ireland Limited for use in acute postoperative pain.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-04-17FDA Approved: ZYNRELEF — Supplemental Application (Heron Therapeutics, Inc.)
The FDA approved a supplemental application for ZYNRELEF (bupivacaine and meloxicam) from Heron Therapeutics, Inc., expanding the regulatory…
-
EMA approval · 2025-03-05EMA Authorised: Dynastat (parecoxib sodium) — Pfizer Europe MA EEIG
The EMA authorised Dynastat (parecoxib sodium) for postoperative pain management in the EU, with Pfizer Europe MA EEIG as the marketing auth…
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for ketorolac tromethamine from Fresenius Kabi USA, LLC, indicating clearance of a modification …
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Ketorolac Tromethamine from Teva Pharmaceuticals USA, Inc., under an ANDA to update the approved…
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA has approved a supplemental application for Ketorolac Tromethamine from Camber Pharmaceuticals, indicating an administrative/approva…
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Hospira, Inc.)
FDA approves Hospira's supplemental application for ketorolac tromethamine, a generic NSAID. The approval pertains to a supplemental change …
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Chartwell RX, LLC)
The FDA approved Chartwell RX, LLC's supplemental application for ketorolac tromethamine (ANDA210616), confirming changes to the approved ge…
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for Ketorolac tromethamine (generic) from Eugia US LLC under ANDA 212939.
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Civica, Inc.)
FDA approved a supplemental application for Civica's ketorolac tromethamine product, enabling a generic approval.
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Nephron Pharmaceuticals Corporation)
FDA approved a supplemental application for Ketorolac tromethamine filed by Nephron Pharmaceuticals Corporation under an ANDA.
-
FDA approval · 2024-11-21FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for Ketorolac Tromethamine by Alembic Pharmaceuticals Inc., indicating approval of an update to an e…
-
FDA approval · 2024-10-31FDA Approved: HYDROCODONE BITARTRATE AND ACETAMINOPHEN — Supplemental Application (Eywa Pharma Inc)
FDA approved Eywa Pharma Inc's supplemental application for hydrocodone bitartrate and acetaminophen (hydrocodone/acetaminophen) under ANDA …
-
FDA approval · 2024-09-24FDA Approved: ZYNRELEF — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for ZYNRELEF (bupivacaine and meloxicam) by Heron Therapeutics, Inc.
-
FDA approval · 2024-07-26FDA Approved: KETOROLAC TROMETHAMINE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for a ketorolac tromethamine product by Fresenius Kabi USA, LLC under the ANDA pathway. This action …
-
FDA approval · 2024-03-26FDA Approved: KETOROLAC TROMETHAMINE — Original Application (Leading Pharma, LLC)
FDA approved an original application for Ketorolac tromethamine from Leading Pharma, LLC, confirming the approval of a generic NSAID for sho…
-
FDA approval · 2024-01-26FDA Approved: SUFENTANIL CITRATE — Supplemental Application (Hospira, Inc.)
The FDA approved Hospira's supplemental application for sufentanil citrate, finalizing an additional regulatory action for this generic opio…
-
FDA approval · 2023-12-15FDA Approved: DSUVIA — Supplemental Application (AcelRx Pharmaceuticals, Inc.)
FDA approved a supplemental application for DSUVIA (sufentanil) by AcelRx Pharmaceuticals, Inc., pertaining to this analgesic product.
-
FDA approval · 2023-12-15FDA Approved: MEPERIDINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.’s supplemental application for Meperidine Hydrochloride, approving a generic version of this opi…
-
FDA approval · 2023-12-14FDA Approved: HYDROMORPHONE HYDROCHLORIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved hydromorphone hydrochloride from Hikma Pharmaceuticals USA Inc. under Original Application NDA217812 for pain management.
-
FDA approval · 2023-11-28FDA Approved: EXPAREL — Supplemental Application (Pacira Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EXPAREL (bupivacaine) from Pacira Pharmaceuticals, Inc. This action approves changes to the …